- Home
- TNGX vs USGOW Comparison
TNGX vs USGOW Comparison
Compare TNGX & USGOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- USGOW
- Stock Information
- Founded
- TNGX 2014
- USGOW 2015
- Country
- TNGX United States
- USGOW Canada
- Employees
- TNGX N/A
- USGOW N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- USGOW Precious Metals
- Sector
- TNGX Health Care
- USGOW Basic Materials
- Exchange
- TNGX Nasdaq
- USGOW Nasdaq
- Market Cap
- TNGX 351.2M
- USGOW N/A
- IPO Year
- TNGX N/A
- USGOW N/A
- Fundamental
- Price
- TNGX $6.01
- USGOW $0.85
- Analyst Decision
- TNGX Strong Buy
- USGOW
- Analyst Count
- TNGX 6
- USGOW 0
- Target Price
- TNGX $12.20
- USGOW N/A
- AVG Volume (30 Days)
- TNGX 2.7M
- USGOW 16.4K
- Earning Date
- TNGX 08-06-2025
- USGOW 02-14-2025
- Dividend Yield
- TNGX N/A
- USGOW N/A
- EPS Growth
- TNGX N/A
- USGOW N/A
- EPS
- TNGX N/A
- USGOW N/A
- Revenue
- TNGX $40,990,000.00
- USGOW N/A
- Revenue This Year
- TNGX N/A
- USGOW N/A
- Revenue Next Year
- TNGX N/A
- USGOW N/A
- P/E Ratio
- TNGX N/A
- USGOW N/A
- Revenue Growth
- TNGX 10.09
- USGOW N/A
- 52 Week Low
- TNGX $1.03
- USGOW $0.27
- 52 Week High
- TNGX $12.02
- USGOW $2.80
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- USGOW N/A
- Support Level
- TNGX $5.34
- USGOW N/A
- Resistance Level
- TNGX $6.40
- USGOW N/A
- Average True Range (ATR)
- TNGX 0.50
- USGOW 0.00
- MACD
- TNGX -0.02
- USGOW 0.00
- Stochastic Oscillator
- TNGX 84.08
- USGOW 0.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.